HomeCompareNBSE vs VYM

NBSE vs VYM: Dividend Comparison 2026

NBSE yields 529.10% · VYM yields 2.41%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NBSE wins by $95355.94M in total portfolio value
10 years
NBSE
NBSE
● Live price
529.10%
Share price
$0.38
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$95355.96M
Annual income
$69,511,989,565.27
Full NBSE calculator →
VYM
Vanguard High Dividend Yield ETF
● Live price
2.41%
Share price
$145.48
Annual div
$3.51
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.8K
Annual income
$278.55
Full VYM calculator →

Portfolio growth — NBSE vs VYM

📍 NBSE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNBSEVYM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NBSE + VYM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NBSE pays
VYM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NBSE
Annual income on $10K today (after 15% tax)
$44,973.54/yr
After 10yr DRIP, annual income (after tax)
$59,085,191,130.48/yr
VYM
Annual income on $10K today (after 15% tax)
$205.23/yr
After 10yr DRIP, annual income (after tax)
$236.77/yr
At 15% tax rate, NBSE beats the other by $59,085,190,893.71/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NBSE + VYM for your $10,000?

NBSE: 50%VYM: 50%
100% VYM50/50100% NBSE
Portfolio after 10yr
$47678.00M
Annual income
$34,755,994,921.90/yr
Blended yield
72.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NBSE right now

NBSE
Analyst Ratings
3
Buy
3
Hold
Consensus: Buy
Altman Z
-10.6
Piotroski
2/9
VYM
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NBSE buys
0
VYM buys
0
No recent congressional trades found for NBSE or VYM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNBSEVYM
Forward yield529.10%2.41%
Annual dividend / share$2.00$3.51
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$95355.96M$27.8K
Annual income after 10y$69,511,989,565.27$278.55
Total dividends collected$93138.90M$2.6K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: NBSE vs VYM ($10,000, DRIP)

YearNBSE PortfolioNBSE Income/yrVYM PortfolioVYM Income/yrGap
1← crossover$63,610$52,910.05$11,151$241.44+$52.5KNBSE
2$382,606$314,543.11$12,413$246.79+$370.2KNBSE
3$2,177,551$1,768,162.86$13,794$251.79+$2.16MNBSE
4$11,734,902$9,404,922.59$15,306$256.47+$11.72MNBSE
5$59,924,074$47,367,729.01$16,960$260.84+$59.91MNBSE
6$290,177,156$226,058,396.40$18,768$264.92+$290.16MNBSE
7$1,333,544,009$1,023,054,452.33$20,745$268.71+$1333.52MNBSE
8$5,820,882,501$4,393,990,410.63$22,905$272.24+$5820.86MNBSE
9$24,153,246,984$17,924,902,708.82$25,265$275.51+$24153.22MNBSE
10$95,355,963,839$69,511,989,565.27$27,842$278.55+$95355.94MNBSE

NBSE vs VYM: Complete Analysis 2026

NBSEStock

NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

Full NBSE Calculator →

VYMETF

Seeks to track the performance of the FTSE High Dividend Yield Index, which measures the investment return of common stocks of companies characterized by high dividend yields. Provides a convenient way to track the performance of stocks that are forecasted to have above-average dividend yields. Follows a passively managed, full-replication approach.

Full VYM Calculator →
📬

Get this NBSE vs VYM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NBSE vs SCHDNBSE vs JEPINBSE vs ONBSE vs KONBSE vs MAINNBSE vs VIGNBSE vs DGRONBSE vs HDV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.